Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
After graduating, he worked as an IT consultant for a listed company before becoming self-employed, during which time he worked for various DAX-listed companies and a large Swiss insurance company, among others.
Since 2009, he has been exclusively involved in the capital markets, where he was able to gain experience as a day and swing trader, in investor relations and at board level. He was able to live out his passion for numbers in the controlling department of a securities trading house.
For him, fundamental analysis paired with the correct reading of the price action of a market provides the basis for successful trading.
Commented by Armin Schulz
Commented by Armin Schulz on May 8th, 2026 | 07:15 CEST
The Clock Is Ticking in Europe: How Group Eleven, Volkswagen, and thyssenkrupp Are Positioning for the Transition
The global economy is being shaken up by three major forces: the push for decarbonization, geopolitical tensions, and the race toward electromobility. For the steel industry in Europe, this means a tough transition—after all, it accounts for 7% of greenhouse gas emissions. At the same time, the EU mandates that by 2030, one-tenth of strategic raw materials must come from domestic sources. Vehicle manufacturers, in turn, are grappling with Scope 3 emissions from their supply chains. Energy prices are skyrocketing, supply chains are breaking down—but that is precisely where opportunities lie. We take a look at the current situation at Group Eleven Resources, Volkswagen, and thyssenkrupp.
Read
Commented by Armin Schulz on May 7th, 2026 | 08:45 CEST
From Niche Metal to Strategic Asset: Antimony Resources Gains Relevance for Rheinmetall and BASF
Created and published on behalf of Antimony Resources Corp.
What was long considered an obscure niche metal is now critical to the defence, chemical, and energy sectors. Antimony is used to harden alloys, improve flame resistance in plastics, and support certain battery technologies. At the same time, China controls 70% of production and strictly limits its exports. The result is price spikes of over 400% within two years. Without independent sources, Western industries risk being paralyzed. This is not a theoretical scenario, but an acute reality. Reason enough to take a closer look at the defence contractor Rheinmetall, the up-and-coming antimony producer Antimony Resources, and the chemical company BASF.
Read
Commented by Armin Schulz on May 7th, 2026 | 08:20 CEST
Setbacks in the gold sector: Barrick Mining, Kobo Resources, and Newmont now offer a second chance to get in
The 2026 gold rally knows no bounds. The current gold price stands at around USD 4,700 per ounce, driven by Middle East conflicts, the Fed's interest rate stabilization, and an unprecedented buying spree by central banks. Any correction is immediately absorbed. Inflation fears and the collapse of the US Dollar system are driving long-term bulls. While ETF investors are following suit and Asian households are chasing records, one question remains: Which mining operators can turn this frenzy into profits? Amid the tension between geopolitical escalation and structural demand, Barrick Mining, Kobo Resources, and Newmont are coming into focus, each with its own roadmap for the next price surge.
Read
Commented by Armin Schulz on May 6th, 2026 | 07:35 CEST
BP, Zefiro Methane, and Shell: How to Profit from Methane Abatement and Rising Oil Prices
Geopolitical tensions, such as the recent conflict with Iran, are driving oil prices sky-high. BP and Shell, in particular, are benefiting from this with robust cash flows. But the industry is changing: millions of long-abandoned wells are leaking methane, an aggressive greenhouse gas. This is creating a new, extremely lucrative market for specialists. Zefiro Methane focuses on the professional sealing of these contaminated sites. While BP and Shell bear the financial and regulatory responsibility, specialized, agile service providers handle the operational implementation. It is precisely at this intersection of fossil fuel value creation and environmental management that BP, Zefiro Methane, and Shell operate today.
Read
Commented by Armin Schulz on May 6th, 2026 | 07:25 CEST
Countdown to a Tungsten Shortage: Why Almonty Industries Is Reaping Disproportionate Benefits Right Now
By mid-2026, the chip industry could be in a tight spot. Not because of a lack of factories, but because of a gas that hardly anyone knows about: tungsten hexafluoride (WF6). Japanese suppliers have warned Korean semiconductor companies. Their own stockpiles will only last until summer. Not because the world is ending. But because China is steadily turning off the tungsten tap. One company has long been positioned to fill the gap: Almonty Industries. Those looking to invest in tungsten can hardly avoid this key supplier.
Read
Commented by Armin Schulz on May 5th, 2026 | 07:35 CEST
A Billion-Dollar Market in the Shadow of E-Mobility – Plug Power, dynaCERT, and Daimler Truck Unlock the Potential
Geopolitical tensions are exposing the risks of reliance on fossil fuels. At the same time, pressure is mounting on logistics and heavy-duty transport to decarbonize economically. While e-mobility is making strides in passenger vehicles, long-haul and construction fleets remain a challenge. Range, frequency, and existing fleets are forcing a rethink. This is precisely where a market is emerging for retrofit solutions with immediate impact, hydrogen integration, and more efficient powertrains. Immediate CO₂ and cost benefits are taking precedence over purely futuristic visions. Plug Power, dynaCERT, and Daimler Truck are addressing this tension with very different but complementary approaches.
Read
Commented by Armin Schulz on May 5th, 2026 | 07:10 CEST
How to Capitalize on Two of the Greatest Crises of Our Time – Thanks to Novo Nordisk, MustGrow Biologics, and Bayer
Created and published on behalf of MustGrow Biologics Corp.
While the world battles an obesity epidemic that has turned Novo Nordisk into a cash cow, a potential conflict with Iran threatens to tear apart global agricultural supply chains. More than 2.5 billion people are overweight, while war-induced fertilizer shortages could destroy crops. Two seemingly contradictory crises collide—pharmaceutical solutions for obesity on one side, biological crop protection products against famine on the other. It is precisely in this tension that three companies, each pursuing different approaches, are operating: Novo Nordisk, MustGrow Biologics, and Bayer.
Read
Commented by Armin Schulz on May 4th, 2026 | 07:10 CEST
Drone Boom Boosts Volatus Aerospace – Nearly 100% Upside Potential! Get in Before the Crowd
Imagine a company that not only builds drones but also manages entire operations remotely—from a central hub across hundreds of kilometres. That is exactly what this Canadian provider has mastered, having spent years serving pipeline operators and energy utilities. Today, even NATO member states are adopting this technology. In March 2026, the company made its debut on the Toronto Stock Exchange. But what is driving this story? The numbers, orders, and a strategic realignment paint the picture of a serious player in a billion-dollar market.
Read
Commented by Armin Schulz on April 30th, 2026 | 07:10 CEST
The Hidden Gem Among Gold Stocks: Lahontan Gold on Its Way to Becoming a Gold Producer
The past nine weeks have seen more happen at Lahontan Gold than at many commodity companies in two years. A series of drilling announcements, financing deals, and strategic personnel changes paints a picture of a Nevada-based developer that is deliberately accelerating its transition from explorer to future producer. For investors looking to identify early on where substance meets a clear roadmap, it is worth taking a look at the news since late February—it reads like a roadmap.
Read
Commented by Armin Schulz on April 30th, 2026 | 07:00 CEST
Weight-Loss Injections, Cancer Cell Inhibitors & the Power of Algorithms: Adding Potential to Your Portfolio with Novo Nordisk, Vidac Pharma, and Evotec
The healthcare market faces a paradoxical scenario in 2026. Public health funds are groaning under record spending, while groundbreaking technologies are redefining medicine. AI-driven drug discovery and personalized therapies promise efficiency gains, but regulatory hurdles and price wars are causing stock prices to fluctuate. In this complex landscape, the wheat is being separated from the chaff. Three distinct biotech strategies could now provide the decisive edge. Novo Nordisk dominates the mass market for metabolic diseases, Vidac Pharma is tackling cancer in novel ways, and Evotec is digitizing the entire drug discovery process.
Read